Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A Cochrane Library review involving Oxford University researchers shows that hormone replacement therapy (HRT) does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke.

Picture of patient holding box of pills and a glass of water to take them.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Renewal of the Novo Nordisk – University of Oxford Fellowship Programme

Leading global healthcare company Novo Nordisk has deepened its partnership with the University of Oxford by announcing £18.5 million of funding for a further 20 Postdoctoral Fellows in this prestigious scientific research programme, over the next nine years. This expanded collaboration also introduces an innovative ‘Springboard Fellowship’, which offers selected fellows an extra two years of funding to further advance their research and professional development.